Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Consensus Rating of “Hold” from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have earned a consensus rating of “Hold” from the twenty-two analysts that are covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $106.20.

Several research firms have commented on ZBH. Robert W. Baird reiterated a “neutral” rating and issued a $100.00 price objective (down from $117.00) on shares of Zimmer Biomet in a report on Tuesday, December 16th. Sanford C. Bernstein upped their price target on shares of Zimmer Biomet from $97.00 to $99.00 and gave the company a “market perform” rating in a research note on Friday, January 9th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, February 10th. The Goldman Sachs Group downgraded Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 target price on the stock. in a research report on Friday, January 9th. Finally, TD Cowen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Monday, January 26th.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $93.33 on Friday. Zimmer Biomet has a 52-week low of $84.59 and a 52-week high of $114.44. The company has a market cap of $18.26 billion, a P/E ratio of 26.36, a P/E/G ratio of 1.96 and a beta of 0.58. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. The stock’s 50-day simple moving average is $92.06 and its 200 day simple moving average is $95.79.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The business had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. During the same period last year, the business earned $2.31 earnings per share. The firm’s revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, sell-side analysts forecast that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet’s payout ratio is presently 27.12%.

Institutional Investors Weigh In On Zimmer Biomet

Several institutional investors and hedge funds have recently bought and sold shares of the company. Legacy Wealth Asset Management LLC boosted its position in shares of Zimmer Biomet by 2.3% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider’s stock worth $460,000 after acquiring an additional 106 shares in the last quarter. Global Retirement Partners LLC lifted its stake in Zimmer Biomet by 7.0% during the third quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock worth $166,000 after purchasing an additional 111 shares during the last quarter. Main Management ETF Advisors LLC lifted its holdings in shares of Zimmer Biomet by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock worth $986,000 after acquiring an additional 112 shares during the last quarter. Cullen Frost Bankers Inc. boosted its stake in shares of Zimmer Biomet by 66.7% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 116 shares in the last quarter. Finally, Generali Asset Management SPA SGR grew its holdings in shares of Zimmer Biomet by 0.9% during the 3rd quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock valued at $1,402,000 after purchasing an additional 122 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.